Medical device maker Medtronic is looking at options to modify its global manufacturing footprint as part of efforts to ...

After decades of development and trials, Medtronic has secured U.S. Food and Drug Administration approval for adaptive ...

Medtronic (NYSE:MDT), which has operations worldwide, is reportedly looking at adjusting its manufacturing footprint amid ...

Medtronic (NYSE: MDT) announced that investigators enrolled the first patient in a pivotal trial of its Prevail drug-coated ...

ViCentra announced today that it appointed Tom Arnold as its new CEO to accelerate growth with the Kaleido automated insulin ...

The U.S. Food and Drug Administration has approved Medtronic's deep brain stimulation system for use in patients with ...

Medtronic received Food and Drug Administration approval for the BrainSense Adaptive deep brain stimulation (DBS) device for ...

The biggest technical challenge for adaptive deep brain stimulation (aDBS) is how small brain signals are, Medtronic's Scott ...

The FDA’s authorisation of Medtronic’s BrainSense follows the system’s receipt of a CE mark in Europe last month.

(NYSE: MDT) announced today that the FDA approved its BrainSense adaptive deep brain stimulation (aDBS) platform.

Shortly after obtaining a greenlight in Europe and after more than 10 years in development, Medtronic has now received the ...

Shares of Medtronic ( MDT -6.63%) were sinking 7.3% as of 11:21 a.m. ET on Tuesday. The decline came after the medical device ...